Does Highmark cover GLP-1s in 2026?

By GLP ChartPolicy checked August 28, 2026

Yes, at a BMI of 40 or higher plus a weight-related condition. Highmark's commercial and ACA plans cover Wegovy and Zepbound for weight loss with prior approval, unless a self-funded employer carved the benefit out.

If your plan denies coverage, two cash programs to check.

No insurance needed.

  1. SnagRx$99 a monthcompounded semaglutideCheck price →SnagRx's homepage shows its 12-month prepaid prices first
  2. Medvi$299 a monthFirst month $179compounded semaglutideCheck price →Straight to MEDVi's GLP-1 sign-up

Does Highmark cover Zepbound and Wegovy?

Yes, with prior approval. Highmark pays for Zepbound and Wegovy for weight loss once your prescriber gets the plan to sign off.

Yes, once the plan signs off. Highmark's commercial and ACA plans cover Zepbound and Wegovy for weight management under policy J-1388. Zepbound is the one the plan prefers. Highmark's own rule is tighter than the drug label. It requires a starting BMI of 40 or higher, plus a qualifying weight-related condition. The label sets the bar at BMI 30. A self-funded employer can still carve the benefit out, so check that your plan has it before you submit.

Applies to commercial fully insured and ACA.

Source: Highmark Pharmacy Policy J-1388 Anti-Obesity (Enhanced), Commercial and Healthcare Reform. Read August 26, 2026.

The full Highmark policy on Zepbound and Wegovy has the BMI bar, the step-therapy rule and what happens at renewal.

Does Highmark cover Mounjaro?

Yes, with prior approval. Highmark pays for Mounjaro once your prescriber gets the plan to sign off.

Highmark covers Mounjaro for type 2 diabetes on its commercial and ACA (Healthcare Reform) plans, under pharmacy policy J-1300. Mounjaro is tirzepatide. The policy names one thing to prove: a type 2 diabetes diagnosis on the record, ICD-10 E11. A member with a claim for another diabetes drug in the past 720 days is approved at the pharmacy counter, with no sign-off at all. Highmark does not cover Mounjaro for weight loss, and will not approve it for obesity on its own. Zepbound is the tirzepatide the FDA approved for weight loss, and it sits under a separate Highmark weight-loss policy.

Applies to commercial non-Medicare.

Source: Pharmacy Policy Bulletin J-1300: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Diabetes - Commercial and Healthcare Reform, policy J-1300. Read August 27, 2026.

The full Highmark policy on Mounjaro has the BMI bar, the step-therapy rule and what happens at renewal.

Does Highmark cover Ozempic?

Yes, with prior approval. Highmark pays for Ozempic once your prescriber gets the plan to sign off.

Highmark covers Ozempic for type 2 diabetes on its commercial drug lists. It usually sits at Tier 2, the plan has to sign off, and a quantity limit applies. Ozempic is not covered for weight loss, because the FDA approved it for type 2 diabetes only. Wegovy is the semaglutide Highmark covers for weight loss. That one runs under a separate weight-loss drug policy, and a self-insured employer can turn it down.

Applies to commercial non-Medicare.

Source: Highmark Comprehensive Formulary (commercial drug list search). Read August 27, 2026.

The full Highmark policy on Ozempic has the BMI bar, the step-therapy rule and what happens at renewal.

Does Highmark cover Rybelsus?

Yes, with prior approval. Highmark pays for Rybelsus once your prescriber gets the plan to sign off.

Highmark covers Rybelsus for type 2 diabetes under pharmacy policy J-1300. The sign-off clears on its own at the pharmacy counter for a member with two things on file. One is a type 2 diabetes diagnosis, ICD-10 E11. The other is a pharmacy claim in the past 720 days for another diabetes drug that is not a GLP-1. A member without that recent history needs a standard sign-off. Rybelsus is not covered for weight loss. The FDA approved it for type 2 diabetes only, and Highmark will not approve it for obesity on its own. Wegovy is the semaglutide for weight loss, and Highmark reviews it under a separate weight-loss policy.

Applies to commercial non-Medicare.

Source: Pharmacy Policy Bulletin: J-1300 Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Diabetes - Commercial and Healthcare Reform, policy J-1300. Read August 28, 2026.

The full Highmark policy on Rybelsus has the BMI bar, the step-therapy rule and what happens at renewal.

This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.

Why you can trust GLP Chart. Same scoring framework applied to every program, and payment never changes a score. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.